These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3293937)

  • 21. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aminoglycoside-induced nephrotoxicity].
    Fabrizii V; Thalhammer F; Hörl WH
    Wien Klin Wochenschr; 1997 Nov; 109(21):830-5. PubMed ID: 9454436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring aminoglycoside therapy.
    Mullins RE; Lampasona V; Conn RB
    Clin Lab Med; 1987 Sep; 7(3):513-29. PubMed ID: 3308292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study.
    Rukholm G; Mugabe C; Azghani AO; Omri A
    Int J Antimicrob Agents; 2006 Mar; 27(3):247-52. PubMed ID: 16472992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibiotic therapy in cystic fibrosis. I. Pharmacologic specifics of antibiotics].
    Sermet-Gaudelus I; Hulin A; Ferroni A; Silly C; Gaillard JL; Berche P; Lenoir G
    Arch Pediatr; 2000 May; 7(5):519-28. PubMed ID: 10855392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Daily single-dose aminoglycoside administration. Therapeutic and economic benefits].
    Knudsen LM; Frimodt-Møller N; Hansen MT; Hippe E
    Ugeskr Laeger; 1993 May; 155(19):1436-41. PubMed ID: 8316969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminoglycoside nephrotoxicity: do time and frequency of administration matter?
    Beauchamp D; Labrecque G
    Curr Opin Crit Care; 2001 Dec; 7(6):401-8. PubMed ID: 11805542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study.
    Crowther Labiris NR; Holbrook AM; Chrystyn H; Macleod SM; Newhouse MT
    Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1711-6. PubMed ID: 10556145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
    Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL
    J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
    Cies JJ; Varlotta L
    Pediatr Pulmonol; 2013 Dec; 48(12):1190-4. PubMed ID: 23281228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.
    Prandota J
    Drugs; 1988 May; 35(5):542-78. PubMed ID: 3293970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Islam S; Oh H; Jalal S; Karpati F; Ciofu O; Høiby N; Wretlind B
    Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.
    Mendelman PM; Smith AL; Levy J; Weber A; Ramsey B; Davis RL
    Am Rev Respir Dis; 1985 Oct; 132(4):761-5. PubMed ID: 3931522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
    Gibson RL; Retsch-Bogart GZ; Oermann C; Milla C; Pilewski J; Daines C; Ahrens R; Leon K; Cohen M; McNamara S; Callahan TL; Markus R; Burns JL
    Pediatr Pulmonol; 2006 Jul; 41(7):656-65. PubMed ID: 16703579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis.
    DeGrado JR; Cios D; Greenwood BC; Kubiak DW; Szumita PM
    J Chemother; 2014 Apr; 26(2):101-4. PubMed ID: 24090527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.